Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to -$3.7 million.

  • Capricor Therapeutics' Net Cash Flow fell 106.47% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.9 million, marking a year-over-year decrease of 182.28%. This contributed to the annual value of -$3.4 million for FY2024, which is 166.93% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Net Cash Flow stood at -$3.7 million, which was up 32.82% from -$5.6 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Net Cash Flow ranged from a high of $57.7 million in Q3 2024 and a low of -$57.1 million during Q4 2024.
  • Its 3-year average for Net Cash Flow is $900,649, with a median of -$768,395 in 2023.
  • Over the last 5 years, Capricor Therapeutics' Net Cash Flow had its largest YoY gain of 6,867.31% in 2024, and its largest YoY loss of 1,099.80% in 2024.
  • Capricor Therapeutics' Net Cash Flow (Quarterly) stood at -$6.0 million in 2021, then skyrocketed by 119.98% to $1.2 million in 2022, then soared by 380.01% to $5.7 million in 2023, then tumbled by 1,099.80% to -$57.1 million in 2024, then crashed by 106.47% to -$3.7 million in 2025.
  • Its last three reported values are -$3.7 million in Q3 2025, -$5.6 million for Q2 2025, and $17.5 million during Q1 2025.